[96a5a0]: / output / allTrials / identified / NCT02980731_identified.json

Download this file

487 lines (487 with data), 21.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
{
"info": {
"nct_id": "NCT02980731",
"official_title": "Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) (VENICE II)",
"inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2\n* Participant has relapsed/refractory disease (received at least one prior therapy)\n* Diagnosis of CLL that meets published 2008 Modified International Workshop on CLL National Cancer Institute - Working Group (IWCLL NCI-WG) Guidelines and:\n\n * has an indication for treatment according to the 2008 Modified IWCLL NCI-WG Guidelines\n * has clinically measurable disease (lymphocytosis > 5 × 10^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam)\n * with or without 17p deletion or TP53 mutation\n * may have been previously treated with a prior B-cell receptor inhibitor therapy\n* Adequate bone marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
"exclusion_criteria": "* Participant has developed Richter's transformation or Prolymphocytic leukemia (PLL)\n* Participant has previously received venetoclax\n* History of active malignancies other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:\n\n * adequately treated in situ carcinoma of the cervix uteri\n * adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin\n * previous malignancy confined and surgically resected (or treated with other modalities) with curative intent\n* Active and uncontrolled autoimmune cytopenias (within 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP), despite low dose corticosteroids\n* Prior allogeneic stem cell transplant",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2",
"criterion": "ECOG performance score",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Participant has relapsed/refractory disease (received at least one prior therapy)",
"criterions": [
{
"exact_snippets": "Participant has relapsed/refractory disease",
"criterion": "disease status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"relapsed",
"refractory"
]
}
]
},
{
"exact_snippets": "received at least one prior therapy",
"criterion": "prior therapy",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "therapy"
}
}
]
}
]
},
{
"line": "* Diagnosis of CLL that meets published 2008 Modified International Workshop on CLL National Cancer Institute - Working Group (IWCLL NCI-WG) Guidelines and:",
"criterions": [
{
"exact_snippets": "Diagnosis of CLL",
"criterion": "chronic lymphocytic leukemia (CLL)",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
},
{
"exact_snippets": "meets published 2008 Modified International Workshop on CLL National Cancer Institute - Working Group (IWCLL NCI-WG) Guidelines",
"criterion": "IWCLL NCI-WG Guidelines compliance",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": true
}
]
}
]
},
{
"line": "* has an indication for treatment according to the 2008 Modified IWCLL NCI-WG Guidelines",
"criterions": [
{
"exact_snippets": "indication for treatment according to the 2008 Modified IWCLL NCI-WG Guidelines",
"criterion": "indication for treatment",
"requirements": [
{
"requirement_type": "guideline",
"expected_value": "2008 Modified IWCLL NCI-WG Guidelines"
}
]
}
]
},
{
"line": "* has clinically measurable disease (lymphocytosis > 5 × 10^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam)",
"criterions": [
{
"exact_snippets": "lymphocytosis > 5 × 10^9/L",
"criterion": "lymphocytosis",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "× 10^9/L"
}
}
]
},
{
"exact_snippets": "palpable and measurable nodes by physical exam",
"criterion": "nodes",
"requirements": [
{
"requirement_type": "palpability",
"expected_value": true
},
{
"requirement_type": "measurability",
"expected_value": true
}
]
},
{
"exact_snippets": "organomegaly assessed by physical exam",
"criterion": "organomegaly",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* with or without 17p deletion or TP53 mutation",
"criterions": [
{
"exact_snippets": "17p deletion",
"criterion": "17p deletion",
"requirements": [
{
"requirement_type": "presence",
"expected_value": {
"operator": "=",
"value": 0,
"unit": "N/A"
}
},
{
"requirement_type": "absence",
"expected_value": {
"operator": "=",
"value": 1,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "TP53 mutation",
"criterion": "TP53 mutation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": {
"operator": "=",
"value": 0,
"unit": "N/A"
}
},
{
"requirement_type": "absence",
"expected_value": {
"operator": "=",
"value": 1,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* may have been previously treated with a prior B-cell receptor inhibitor therapy",
"criterions": [
{
"exact_snippets": "may have been previously treated with a prior B-cell receptor inhibitor therapy",
"criterion": "prior B-cell receptor inhibitor therapy",
"requirements": [
{
"requirement_type": "treatment history",
"expected_value": true
}
]
}
]
},
{
"line": "* Adequate bone marrow function",
"criterions": [
{
"exact_snippets": "Adequate bone marrow function",
"criterion": "bone marrow function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 99 Years",
"criterions": [
{
"exact_snippets": "maximum age of 99 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 99,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Participant has developed Richter's transformation or Prolymphocytic leukemia (PLL)",
"criterions": [
{
"exact_snippets": "Participant has developed Richter's transformation",
"criterion": "Richter's transformation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Participant has developed ... Prolymphocytic leukemia (PLL)",
"criterion": "Prolymphocytic leukemia (PLL)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Participant has previously received venetoclax",
"criterions": [
{
"exact_snippets": "Participant has previously received venetoclax",
"criterion": "venetoclax treatment",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* History of active malignancies other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:",
"criterions": [
{
"exact_snippets": "History of active malignancies other than CLL within the past 2 years",
"criterion": "active malignancies",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 2,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "* adequately treated in situ carcinoma of the cervix uteri",
"criterions": [
{
"exact_snippets": "adequately treated in situ carcinoma of the cervix uteri",
"criterion": "in situ carcinoma of the cervix uteri",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "adequately treated"
}
]
}
]
},
{
"line": "* adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin",
"criterions": [
{
"exact_snippets": "adequately treated basal cell carcinoma",
"criterion": "basal cell carcinoma",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "adequately treated"
}
]
},
{
"exact_snippets": "adequately treated ... localized squamous cell carcinoma of the skin",
"criterion": "squamous cell carcinoma of the skin",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "adequately treated"
},
{
"requirement_type": "localization",
"expected_value": "localized"
}
]
}
]
},
{
"line": "* previous malignancy confined and surgically resected (or treated with other modalities) with curative intent",
"criterions": [
{
"exact_snippets": "previous malignancy confined",
"criterion": "previous malignancy",
"requirements": [
{
"requirement_type": "status",
"expected_value": "confined"
}
]
},
{
"exact_snippets": "previous malignancy ... surgically resected (or treated with other modalities) with curative intent",
"criterion": "previous malignancy",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "surgically resected or treated with other modalities with curative intent"
}
]
}
]
},
{
"line": "* Active and uncontrolled autoimmune cytopenias (within 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP), despite low dose corticosteroids",
"criterions": [
{
"exact_snippets": "Active and uncontrolled autoimmune cytopenias (within 2 weeks prior to screening)",
"criterion": "autoimmune cytopenias",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
},
{
"requirement_type": "control",
"expected_value": "uncontrolled"
},
{
"requirement_type": "time frame",
"expected_value": "within 2 weeks prior to screening"
}
]
},
{
"exact_snippets": "autoimmune hemolytic anemia (AIHA)",
"criterion": "autoimmune hemolytic anemia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "idiopathic thrombocytopenic purpura (ITP)",
"criterion": "idiopathic thrombocytopenic purpura",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "despite low dose corticosteroids",
"criterion": "response to corticosteroids",
"requirements": [
{
"requirement_type": "response",
"expected_value": "despite low dose corticosteroids"
}
]
}
]
},
{
"line": "* Prior allogeneic stem cell transplant",
"criterions": [
{
"exact_snippets": "Prior allogeneic stem cell transplant",
"criterion": "allogeneic stem cell transplant",
"requirements": [
{
"requirement_type": "prior",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}